Onconetix, Inc. Deferred Offering Costs
Onconetix, Inc. (ONCO) had Deferred Offering Costs of $300.00 thousand as of 2024-03-31, per its 10-Q filed 2024-05-20.
Discontinued › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current
us-gaap:DeferredOfferingCosts · last filed 2024-05-20
- 2024-03-31: Deferred Offering Costs $300.00K.
- 2022-09-30: Deferred Offering Costs $125.00K.
- 2022-06-30: Deferred Offering Costs $187.50K.
- 2022-03-31: Deferred Offering Costs $233.80K.
| Period end | Deferred Offering Costs |
|---|---|
| 2024-03-31 | $300.00K 10-Q · filed 2024-05-20 |
| 2022-09-30 | $125.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $187.50K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $233.80K 10-Q · filed 2022-05-13 |
| 2021-09-30 | $96.31K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |